When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
Autoimmune encephalitis
Epilepsy
LGI1
NMDA
Testing
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
06
10
2021
accepted:
06
11
2021
revised:
05
11
2021
pubmed:
25
11
2021
medline:
24
5
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
Seizures represent a core symptom of autoimmune encephalitides with specific therapeutic issues. To date, patients with new-onset seizures or established epilepsy are not systematically tested for autoimmune antibodies. We aimed to identify clinical and paraclinical criterion that could help to select patients requiring additional autoimmune antibodies serum and cerebrospinal fluid (CSF) detection. In this retrospective single center study from the French Salpêtrière Hospital, data from 286 adult patients with epilepsy who received an autoantibody assay for the first time were analyzed. All patients were evaluated at our institution between January 2007 and December 2018 for assessment of new-onset epilepsy (n = 90) or established epilepsy (n = 196). We only analyzed patients that were screened for autoimmune antibodies. Demographic, clinical and neuroimaging measures were compared between patients with and without autoimmune encephalitis using Fisher's exact test for categorical variables and Welch's t test for continuous variables. Our primary goal was to identify significant factors that differentiated patients with and without autoimmune encephalitis. We identified 27 patients with autoimmune epilepsy (9.4% of the patients who had been tested for autoantibodies). The significant factors differentiating patients with and without autoimmune encephalitis were: (i) the existence of a new-onset focal epilepsy + (e.g., newly diagnosed epilepsy < 6 months associated with additional symptoms, mainly cognitive or psychiatric symptoms), (ii) the presence of faciobrachial dystonic seizures very suggestive of anti- Leucine-rich glioma inactivated 1 (LGI1) encephalitis, and (iii) the presence of magnetic resonance imaging (MRI) abnormalities suggestive of encephalitis. New-onset focal seizures combined with cognitive or psychiatric symptoms support the test for autoimmune antibodies. Further clinical already known red flags for an autoimmune origin are the presence of faciobrachial dystonic seizures and MRI signal changes consistent with encephalitis. On the other hand, isolated new-onset seizures and chronic epilepsy, even with associated symptoms, seem rarely linked to autoimmune encephalitis and should not lead to systematic testing.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Seizures represent a core symptom of autoimmune encephalitides with specific therapeutic issues. To date, patients with new-onset seizures or established epilepsy are not systematically tested for autoimmune antibodies. We aimed to identify clinical and paraclinical criterion that could help to select patients requiring additional autoimmune antibodies serum and cerebrospinal fluid (CSF) detection.
METHODS
METHODS
In this retrospective single center study from the French Salpêtrière Hospital, data from 286 adult patients with epilepsy who received an autoantibody assay for the first time were analyzed. All patients were evaluated at our institution between January 2007 and December 2018 for assessment of new-onset epilepsy (n = 90) or established epilepsy (n = 196). We only analyzed patients that were screened for autoimmune antibodies. Demographic, clinical and neuroimaging measures were compared between patients with and without autoimmune encephalitis using Fisher's exact test for categorical variables and Welch's t test for continuous variables. Our primary goal was to identify significant factors that differentiated patients with and without autoimmune encephalitis.
RESULTS
RESULTS
We identified 27 patients with autoimmune epilepsy (9.4% of the patients who had been tested for autoantibodies). The significant factors differentiating patients with and without autoimmune encephalitis were: (i) the existence of a new-onset focal epilepsy + (e.g., newly diagnosed epilepsy < 6 months associated with additional symptoms, mainly cognitive or psychiatric symptoms), (ii) the presence of faciobrachial dystonic seizures very suggestive of anti- Leucine-rich glioma inactivated 1 (LGI1) encephalitis, and (iii) the presence of magnetic resonance imaging (MRI) abnormalities suggestive of encephalitis.
CONCLUSION
CONCLUSIONS
New-onset focal seizures combined with cognitive or psychiatric symptoms support the test for autoimmune antibodies. Further clinical already known red flags for an autoimmune origin are the presence of faciobrachial dystonic seizures and MRI signal changes consistent with encephalitis. On the other hand, isolated new-onset seizures and chronic epilepsy, even with associated symptoms, seem rarely linked to autoimmune encephalitis and should not lead to systematic testing.
Identifiants
pubmed: 34816332
doi: 10.1007/s00415-021-10894-y
pii: 10.1007/s00415-021-10894-y
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3109-3118Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Fisher RS, Acevedo C, Arzimanoglou A et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482. https://doi.org/10.1111/epi.12550
doi: 10.1111/epi.12550
pubmed: 24730690
Scheffer IE, Berkovic S, Capovilla G et al (2017) ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia 58:512–521. https://doi.org/10.1111/epi.13709
doi: 10.1111/epi.13709
pubmed: 28276062
pmcid: 5386840
De Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH et al (2019) Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA
doi: 10.1212/WNL.0000000000007475
pubmed: 30979857
pmcid: 6537134
Newman MP, Blum S, Wong RCW et al (2016) Autoimmune encephalitis. Intern Med J 46:148–157. https://doi.org/10.1111/imj.12974
doi: 10.1111/imj.12974
pubmed: 26899887
Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9
doi: 10.1016/S1474-4422(15)00401-9
pubmed: 26906964
pmcid: 5066574
Dubey D, Singh J, Britton JW, Pittock SJ (2017) Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 58:1181–1189. https://doi.org/10.1111/epi.13797
doi: 10.1111/epi.13797
pubmed: 28555833
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, The RECORD Working Committee (2015) The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. https://doi.org/10.1371/journal.pmed.1001885
doi: 10.1371/journal.pmed.1001885
pubmed: 26440803
pmcid: 4595218
Macher S, Zimprich F, De Simoni D, Höftberger R, Rommer PS (2018) Management of autoimmune encephalitis: an observational monocentric study of 38 patients. Front Immunol. https://doi.org/10.3389/fimmu.2018.02708
doi: 10.3389/fimmu.2018.02708
pubmed: 30524441
pmcid: 6262885
Dalmau J, Gleichman AJ, Hughes EG et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2
doi: 10.1016/S1474-4422(08)70224-2
pubmed: 18851928
pmcid: 2607118
Dubey D, Pittock SJ, Kelly CR et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis: autoimmune encephalitis. Ann Neurol 83:166–177. https://doi.org/10.1002/ana.25131
doi: 10.1002/ana.25131
pubmed: 29293273
pmcid: 6011827
Brenner T, Sills GJ, Hart Y et al (2013) Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 54:1028–1035. https://doi.org/10.1111/epi.12127
doi: 10.1111/epi.12127
pubmed: 23464826
Dubey D, Alqallaf A, Hays R et al (2017) Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 74:397–402. https://doi.org/10.1001/jamaneurol.2016.5429
doi: 10.1001/jamaneurol.2016.5429
pubmed: 28166327
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) the frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis 54:899–904. https://doi.org/10.1093/cid/cir1038
doi: 10.1093/cid/cir1038
pubmed: 22281844
pmcid: 3297648
Van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ (2017) The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 13:290–301. https://doi.org/10.1038/nrneurol.2017.43
doi: 10.1038/nrneurol.2017.43
pubmed: 28418022
Dubey D, Samudra N, Gupta P et al (2015) Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure 29:143–147. https://doi.org/10.1016/j.seizure.2015.04.007
doi: 10.1016/j.seizure.2015.04.007
pubmed: 26076858
Scheer S, John RM (2016) Anti–N-methyl-D-aspartate receptor encephalitis in children and adolescents. J Pediatr Health Care 30:347–358. https://doi.org/10.1016/j.pedhc.2015.09.004
doi: 10.1016/j.pedhc.2015.09.004
pubmed: 26507948
Lai M, Huijbers MGM, Lancaster E et al (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785. https://doi.org/10.1016/S1474-4422(10)70137-X
doi: 10.1016/S1474-4422(10)70137-X
pubmed: 20580615
pmcid: 3086669
Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165. https://doi.org/10.1016/S1474-4422(12)70310-1
doi: 10.1016/S1474-4422(12)70310-1
pubmed: 23290630
pmcid: 3563251
Gresa-Arribas N, Ariño H, Martínez-Hernández E et al (2015) Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS ONE. https://doi.org/10.1371/journal.pone.0121364
doi: 10.1371/journal.pone.0121364
pubmed: 25774787
pmcid: 4361655
Irani SR, Michell AW, Lang B et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900. https://doi.org/10.1002/ana.22307
doi: 10.1002/ana.22307
pubmed: 21416487
Daif A, Lukas RV, Issa NP et al (2018) Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav 80:331–336. https://doi.org/10.1016/j.yebeh.2018.01.021
doi: 10.1016/j.yebeh.2018.01.021
pubmed: 29433947
de Bruijn MAAM, Bastiaansen AEM, Mojzisova H et al (2021) Antibodies contributing to focal epilepsy signs and symptoms score. Ann Neurol 89:698–710. https://doi.org/10.10002/ana.26013
doi: 10.10002/ana.26013
pubmed: 33427313
pmcid: 8048471
Britton JW, Dalmau J (2019) Recognizing autoimmune encephalitis as a cause of seizures treating cause and not effect. Neurology 92:877–878. https://doi.org/10.1212/WNL.0000000000007444
doi: 10.1212/WNL.0000000000007444
pubmed: 30979858
Geis C, Planaguma J, Carreño M, Graus F, Dalmau J (2019) Autoimmune seizures and epilepsy. J Clin Invest 129:926–940. https://doi.org/10.1172/JCI125178
doi: 10.1172/JCI125178
pubmed: 30714986
pmcid: 6391086
Dittrich TD, Baumann SM, Semmlack S, De Marchis GM, Hunziker S, Rüegg S et al (2021) Diagnostic yield of cerebrospinal fluid analysis in status epilepticus: an 8-year cohort study. J Neurol 268(9):3325–3336. https://doi.org/10.1007/s00415-021-10447-3
doi: 10.1007/s00415-021-10447-3
pubmed: 33666722
pmcid: 8357741
Vogrig A, Joubert B, Andre-Obadia N, Gigli GL, Rheims S, Honnorat J (2019) Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia 60:1508–1525. https://doi.org/10.1111/epi.16282
doi: 10.1111/epi.16282
pubmed: 31283859
Ottman R, Lipton RB, Ettinger AB et al (2011) Comorbidities of epilepsy: results from the epilepsy comorbidities and health (EPIC) survey. Epilepsia 52:308–315. https://doi.org/10.1111/j.1528-1167.2010.02927.x
doi: 10.1111/j.1528-1167.2010.02927.x
pubmed: 21269285
Brooks-Kayal AR, Bath KG, Berg AT et al (2013) Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54:44–60. https://doi.org/10.1111/epi.12298
doi: 10.1111/epi.12298
pubmed: 23909853
pmcid: 3924317
Helmstaedter C, Witt JA (2017) Epilepsy and cognition: a bidirectional relationship? Seizure 49:83–89. https://doi.org/10.1016/j.seizure.2017.02.017
doi: 10.1016/j.seizure.2017.02.017
pubmed: 28284559
Ettinger A, Reed M, Cramer J (2004) Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 63:1008–1014. https://doi.org/10.1212/01.wnl.0000138430.11829.61
doi: 10.1212/01.wnl.0000138430.11829.61
pubmed: 15452291
Baysal-Kirac L, Tuzun E, Altindag E et al (2016) Are there any specific EEG findings in autoimmune epilepsies? Clin EEG Neurosci 47:224–234. https://doi.org/10.1177/1550059415595907
doi: 10.1177/1550059415595907
pubmed: 26240088
Heine J, Pruss H, Bartsch T, Ploner CJ, Paul F, Finke C (2015) Imaging of autoimmune encephalitis—relevance for clinical practice and hippocampal function. Neuroscience 309:68–83. https://doi.org/10.1016/j.neuroscience.2015.05.037
doi: 10.1016/j.neuroscience.2015.05.037
pubmed: 26012492